For the growing number of patients with advanced heart failure, successful outcomes depend on consistent, evidence-based clinical management and expert heart failure practitioners. The highly skilled multidisciplinary team at the Center for Advanced Heart Failure Treatment delivers comprehensive care for the most complex, endstage heart failure patients. They offer the full spectrum of therapeutic options, from traditional treatment to breakthrough approaches on the forefront of technology.
Minneapolis Heart Institute® physicians are in close communication with partnering physicians throughout the patient’s care—from diagnosis of early heart failure through advanced treatment. They are available 24/7 to discuss any heart failure concerns.
The team includes:
- Specialized cardiologists who are board certified in Advanced Heart Failure Therapies and Transplant
- Cardiothoracic surgeons
- Doctors of pharmacy
- Certified nurse practitioners and physician assistants
- Nurses, including specialized care coordinators
- Social workers
- Exercise physiologists
- Support staff
Immediate Transfer of Patients In Cardiogenic Shock
Patients in cardiogenic shock who require advanced mechanical support benefit from the rapid response and transfer protocols that are supported by the Minneapolis Heart Institute®’s established network of partner community hospitals and its highly skilled and experienced clinical team.
When tailored medical therapy is not enough, heart transplantation may offer a life-saving treatment option for patients with end-stage heart failure. Since establishing a new team and reorganizing the program in 2010, 38 transplant procedures have been performed at Minneapolis Heart Institute® at Abbott Northwestern Hospital (as of June 2012). Abbott Northwestern’s Heart Transplant Program is Centers for Medicare & Medicaid Services certified.
Ventricular Assist Devices (VADs)
A variety of temporary and long-term mechanical circulatory support devices are available, specific to each patient’s need. These devices are an important option as a bridge to cardiovascular recovery, a bridge to transplantation or as a destination therapy for permanent support. The VAD Program received Joint Commission Certification for VAD Destination Therapy in November 2010.
Our cardio-oncology program evaluates and treats the cardio-toxic side effects of chemotherapeutic agents and identifies patients at risk for future adverse events. Working closely with oncologists, the goal of the cardio-oncology team is to help patients complete their treatment, giving them the best possible chance for a cure.
With the support of the Minneapolis Heart Institute Foundation, advanced heart failure specialists are involved in FDA-approved and National Institutes of Health (NIH)-sponsored trials for:
- Novel heart failure therapies
- New generation VADs
- Adult stem cell angiogenesis